Pastuch-Gawolek G, Szreder J, Dominska M, Pielok M, Cichy P, Grymel M
Pharmaceutics. 2023; 15(3).
PMID: 36986774
PMC: 10056414.
DOI: 10.3390/pharmaceutics15030913.
Gupta M, Sharma V, Sharma K, Kumar A, Sharma A, Kazmi I
Pharmaceutics. 2022; 14(7).
PMID: 35890297
PMC: 9320317.
DOI: 10.3390/pharmaceutics14071401.
Nunes M, Silva P, Coelho R, Pinto C, Resende A, Bousbaa H
Front Oncol. 2021; 11:752127.
PMID: 34745981
PMC: 8566917.
DOI: 10.3389/fonc.2021.752127.
Atanasov A, Zotchev S, Dirsch V, Supuran C
Nat Rev Drug Discov. 2021; 20(3):200-216.
PMID: 33510482
PMC: 7841765.
DOI: 10.1038/s41573-020-00114-z.
Nada H, Elkamhawy A, Lee K
Molecules. 2021; 26(3).
PMID: 33494492
PMC: 7865909.
DOI: 10.3390/molecules26030553.
Synergistic Enhancement of Paclitaxel-induced Inhibition of Cell Growth by Metformin in Melanoma Cells.
Ko G, Kim T, Ko E, Park D, Lee Y
Dev Reprod. 2019; 23(2):119-128.
PMID: 31321352
PMC: 6635613.
DOI: 10.12717/DR.2019.23.2.119.
Residual Complexity Does Impact Organic Chemistry and Drug Discovery: The Case of Rufomyazine and Rufomycin.
Choules M, Klein L, Lankin D, McAlpine J, Cho S, Cheng J
J Org Chem. 2018; 83(12):6664-6672.
PMID: 29792329
PMC: 6006449.
DOI: 10.1021/acs.joc.8b00988.
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.
Ojima I, Wang X, Jing Y, Wang C
J Nat Prod. 2018; 81(3):703-721.
PMID: 29468872
PMC: 5869464.
DOI: 10.1021/acs.jnatprod.7b01012.
Prodrug Strategies for Paclitaxel.
Meng Z, Lv Q, Lu J, Yao H, Lv X, Jiang F
Int J Mol Sci. 2016; 17(5).
PMID: 27223283
PMC: 4881612.
DOI: 10.3390/ijms17050796.
Conformationally Constrained and Nanoparticle Targeted Paclitaxels.
Kingston D, Tamarkin L, Paciotti G
Pure Appl Chem. 2015; 84(6):1455-1467.
PMID: 25598555
PMC: 4295212.
DOI: 10.1351/PAC-CON-11-09-02.
The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent.
Kingston D, Snyder J
Acc Chem Res. 2014; 47(8):2682-91.
PMID: 25052294
PMC: 4139185.
DOI: 10.1021/ar500203h.
Drug discovery targeting cell division proteins, microtubules and FtsZ.
Ojima I, Kumar K, Awasthi D, Vineberg J
Bioorg Med Chem. 2014; 22(18):5060-77.
PMID: 24680057
PMC: 4156572.
DOI: 10.1016/j.bmc.2014.02.036.
(3R,4S)-1-(4-Meth-oxy-phen-yl)-2-oxo-4-(3-vinyl-phen-yl)azetidin-3-yl acetate.
Hao X, Xie C, Hao Y, Chang J, Sun X
Acta Crystallogr Sect E Struct Rep Online. 2013; 69(Pt 4):o601.
PMID: 23634128
PMC: 3629641.
DOI: 10.1107/S1600536813007897.
Design and synthesis of simplified taxol analogs based on the T-Taxol bioactive conformation.
Zhao J, Bane S, Snyder J, Hu H, Mukherjee K, Slebodnick C
Bioorg Med Chem. 2011; 19(24):7664-78.
PMID: 22071526
PMC: 3225578.
DOI: 10.1016/j.bmc.2011.10.010.
Molecular dynamics simulation and density functional theory studies on the active pocket for the binding of paclitaxel to tubulin.
Xu S, Chi S, Jin Y, Shi Q, Ge M, Wang S
J Mol Model. 2011; 18(1):377-91.
PMID: 21537957
DOI: 10.1007/s00894-011-1083-7.
Cryoelectron microscopy applications in the study of tubulin structure, microtubule architecture, dynamics and assemblies, and interaction of microtubules with motors.
Downing K, Nogales E
Methods Enzymol. 2010; 483:121-42.
PMID: 20888472
PMC: 4165512.
DOI: 10.1016/S0076-6879(10)83006-X.
Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.
George J, Banik N, Ray S
J Cell Mol Med. 2009; 13(10):4205-18.
PMID: 19473291
PMC: 4496127.
DOI: 10.1111/j.1582-4934.2008.00539.x.
Recent advances in the study of the bioactive conformation of taxol.
Sun L, Simmerling C, Ojima I
ChemMedChem. 2009; 4(5):719-31.
PMID: 19360801
PMC: 3072276.
DOI: 10.1002/cmdc.200900044.
Synthesis and bioactivity of a side chain bridged paclitaxel: A test of the T-Taxol conformation.
Hodge M, Chen Q, Bane S, Sharma S, Loew M, Banerjee A
Bioorg Med Chem Lett. 2009; 19(10):2884-7.
PMID: 19359169
PMC: 2684938.
DOI: 10.1016/j.bmcl.2009.03.063.
Antivascular actions of microtubule-binding drugs.
Schwartz E
Clin Cancer Res. 2009; 15(8):2594-601.
PMID: 19351751
PMC: 2745203.
DOI: 10.1158/1078-0432.CCR-08-2710.